Dr. Christopher M. Kramer, MD
Cardiology (Cardiovascular Disease Physician)
- Medicare participating
At a glance
- Medical school
- University of California, San Francisco School of Medicine (1986)
- Years since graduation
- 40
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 704
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1986Medical school: University of California, San Francisco School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Cardiovascular Disease Physician primary
VA license 0101222224
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Virginia Medical Center Charlottesville, VA
Medical groups
- University of Virginia Physicians Group (1,717 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 704
- Services billed
- 982
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 417 | 410 |
| Established patient office or other outpatient visit, 30-39 minutes | 85 | 77 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 59 | 35 |
| Ct scan of heart structure with contrast | 58 | 58 |
| Ct scan of blood vessels and grafts of heart with contrast | 57 | 57 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 50 | 50 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 48 | 48 |
| Mri scan of heart before and after contrast | 44 | 44 |
| Ultrasound of heart, follow-up | 38 | 38 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 19 | 19 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 7 payments worth $23,054 in total to this clinician.
| Lilly USA, LLC | $22,753 |
|---|---|
| Eli Lilly and Company | $301 |
| Consulting Fee | $14,301 |
|---|---|
| Compensation for services other than consulting (speaking, faculty) | $8,200 |
| Travel and Lodging | $553 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Lilly USA, LLC Aug 20, 2025 | Consulting Fee | $7,600 |
| Lilly USA, LLC Aug 25, 2025 | Compensation for services other than consulting (speaking, faculty) | $7,400 |
| Lilly USA, LLC Aug 20, 2025 | Consulting Fee | $3,200 |
| Lilly USA, LLC Aug 19, 2025 | Consulting Fee | $3,200 |
| Lilly USA, LLC Jul 2, 2025 | Compensation for services other than consulting (speaking, faculty) | $800 |
| Lilly USA, LLC Aug 12, 2025 | Travel and Lodging travel to SYDNEY, Australia · in-kind | $553 |
| Eli Lilly and Company Dec 12, 2025 | Consulting FeeCompany’s descriptionSERVICES TO SUPPORT RESEARCH RELATED ACTIVITIES | $301 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 2 companies. The companies reported $309,901 in research payments for these studies, mostly to the institutions running them.
- Study name not reported
Celgene Corporation - A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic C…
E.r. Squibb & Sons, L.l.c. - A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten in Adults with Symptomatic Non-obstructive Hypertrophic Cardiomyopathy
E.r. Squibb & Sons, L.l.c. - Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.
E.r. Squibb & Sons, L.l.c. · Completed · NCT01996865
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.